Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Nature Communications
|
May 16, 2025
Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial
Yuqin Song, Jun Ma, Huilai Zhang, et al.
Leukemia
|
February 20, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma
Zegeng Chen, He Huang, Huageng Huang, et al.
Cell Reports. Medicine
|
February 11, 2026
A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction
Yi Cao, Yuchen Zhang, Liang Wang, et al.
Blood Cancer Journal
|
March 11, 2026
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study
Qihua Zou, Yi Cao, Liang Wang, et al.
Cancer
|
January 3, 2025
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
Yan Gao, Yunhong Huang, Qingyuan Zhang, et al.
Leukemia
|
February 19, 2020
A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group
Huangming Hong, Yexiong Li, Soon Thye Lim, et al.
Nature Communications
|
June 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial
Qihua Zou, Shenrui Bai, Liang Wang, et al.
Journal of Hematology & Oncology
|
January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Discover Oncology
|
July 2, 2025
Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study
Ling Huang, Yong Yang, Zhenyu Zhao, et al.
Signal Transduction and Targeted Therapy
|
August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Chuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Nature Communications
|
May 16, 2025
Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial
Yuqin Song, Jun Ma, Huilai Zhang, et al.
Leukemia
|
February 20, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma
Zegeng Chen, He Huang, Huageng Huang, et al.
Cell Reports. Medicine
|
February 11, 2026
A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction
Yi Cao, Yuchen Zhang, Liang Wang, et al.
Blood Cancer Journal
|
March 11, 2026
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study
Qihua Zou, Yi Cao, Liang Wang, et al.
Cancer
|
January 3, 2025
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
Yan Gao, Yunhong Huang, Qingyuan Zhang, et al.
Leukemia
|
February 19, 2020
A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group
Huangming Hong, Yexiong Li, Soon Thye Lim, et al.
Nature Communications
|
June 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial
Qihua Zou, Shenrui Bai, Liang Wang, et al.
Journal of Hematology & Oncology
|
January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Discover Oncology
|
July 2, 2025
Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study
Ling Huang, Yong Yang, Zhenyu Zhao, et al.
Signal Transduction and Targeted Therapy
|
August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Chuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Page
of 7